Impact of smoking on psoriasis risk and treatment efficacy: a meta-analysis

Zhou, Hang; Wu, Ruifang; Kong, Yi Wen; Zhao, Ming; Y, Su

doi:10.1177/0300060520964024

Cited by 44 publications

(32 citation statements)

References 68 publications

(222 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The meta-analysis of prevalence studies confirmed the relationship between psoriasis and about 1.7 times greater frequency of smoking [ 61 ]. Moreover, smoking is a well-known disease-aggravating factor, poor treatment-outcome predictor, and cardiovascular event-risk factor [ 62 , 63 ]. Therefore, it is surprising that despite evident negative impact of smoking on psoriasis, patients still continued smoking.…”

Section: Discussionmentioning

confidence: 99%

Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life

Purzycka-Bohdan

Kisielnicka

Zabłotna

et al. 2022

JCM

View full text Add to dashboard Cite

The epidemiology of psoriasis has not been widely assessed in Polish population so far. This study aimed to investigate psoriasis epidemiological situation by evaluating disease course and severity, management, comorbidities, environmental factors, and knowledge about this disorder among psoriatic patients in Poland. A cross-sectional cohort population-based study enrolled 1080 psoriatic patients and 1200 controls. The mean age of psoriasis onset was 27.6 years; 78.24% had type I psoriasis. Positive family history of psoriasis was reported in 44.81% of patients, whereas itch was reported in vast majority of patients (83.33%). Based on PASI score moderate psoriasis was the most common in studied group (mean 12.63 ± 9.33, range 0–67.2). The DLQI score (12.01 ± 7.41, range 0–30.0) indicated a very large effect of psoriasis on the quality of life. Hypertension was the most prevalent comorbidity (33.80%), followed by obesity (16.85%) and dyslipidemia (11.85%). Stress was the foremost cause of disease exacerbation (66.20%); however, infections (44.07%) and seasonal changes (45.09%) had also an impact on the course of psoriasis. Psoriatic patients were more often smokers (37.59%) vs. general population (27.50%; p < 0.0001). In conclusion, epidemiological studies help clinicians in better disease and patient understanding, which may translate into better management and patient compliance.

show abstract

Section: Discussionmentioning

confidence: 99%

Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life

Purzycka-Bohdan

Kisielnicka

Zabłotna

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Environmental and genetic factors both play a role in the development of immune-mediated cutaneous inflammation. Among the most significant environmental factors influencing psoriasis onset or disease severity/activity, are mental and physical stress [ 1 ], alcohol consumption [ 2 ], and smoking [ 3 ]. In addition, a growing body of evidence indicates that excessive body weight, nutritional factors, and diet may exacerbate the clinical manifestations of psoriasis or trigger the onset of the disease [ 4 , 5 , 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Association of Nonalcoholic Hepatic Fibrosis with Body Composition in Female and Male Psoriasis Patients

Brunner

Oláh

Moezzi

et al. 2021

Life

View full text Add to dashboard Cite

Psoriasis has been associated with increased frequency of hepatic diseases. Psoriasis severity, obesity, insulin resistance, aspartate aminotransferase level, platelet count, and alcohol use are significant predictors for advanced fibrosis in psoriasis patients. Although psoriasis patients also present body composition changes (e.g., higher overall body fat, visceral fat and sarcopenia), and these have recently been reported as risk factors for hepatic fibrosis, to date, body composition has not been prospectively investigated in psoriasis in the context of liver fibrosis. In this study anthropometric assessment (body weight and body mass index (BMI)), body composition analysis (body fat%, visceral fat scores and muscle mass%), and liver stiffness measurements (using transient elastography [TE]) were done in 52 psoriasis patients undergoing methotrexate therapy. Fourteen patients (26.9%) had advanced (F3–F4) liver fibrosis. There was no correlation between the patients’ liver stiffness values and the cumulative MTX doses. On the other hand, patients with higher BMI values, total body fat% and visceral fat scores were significantly more likely to present with higher hepatic stiffness values. BMI was a significant predictor of hepatic fibrosis in both genders. In males, body fat% (R = 0.578, p = 0.002) and, especially, visceral fat scores (R = 0.716, p < 0.001) had statistically significant correlation with stiffness scores, while in females only visceral fat scores were statistically significant predictors of the liver stiffness values (R = 0.452, p = 0.023), and body fat% was not (R = 0.187, p = 0.382). Our results suggest that anthropometric data should be assessed differently in female and male psoriasis patients when evaluating liver fibrosis risk.

show abstract

“…Numerous meta-analyzes have tried to elucidate this unknown fact, but the final results have not been consistent. On the one hand, there are authors who reported that smoking influences the therapeutic response in patients and postulated that smokers were less likely to show disease improvement in the disease at 6 months after treatment with biologic agents than non-smokers [ 1 ], and, on the other hand, there have been studies suggesting that active smoking does not significantly affect the response to treatment [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

“…A recent meta-analysis published in 2020 suggests that the number of reports is limited and more studies are needed to confirm the effects of smoking and smoking cessation on the therapeutic response in patients with psoriasis [ 1 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Impact of Smoking on Psoriasis Patients with Biological Therapies in a Bucharest Hospital

Constantin

Bucur

Mutu

et al. 2021

JPM

View full text Add to dashboard Cite

Psoriasis is an immune-mediated chronic inflammatory skin disease with extracutaneous manifestations, that affects about 1–3% of the world’s population. The disease is not life-threatening, but the disability which comes with it is comparable to the disability caused by other serious chronic diseases, such as oncologic or cardiovascular disease. Several risk factors, such as infections, stress, smoking, excessive alcohol consumption and genetic predisposition have been involved in inducing psoriasis. Smoking status is a risk factor for many chronic diseases, including psoriasis. Moreover, recent studies have tried to answer the question of whether smoking also influences the response to biologic therapy in patients with psoriasis. Through the current study, our intention is to find out how smoking affects the response to biologic treatment. A hospital-based cross-sectional, observational, non-interventional, retrospective study of moderate and severe psoriasis patients receiving biologic treatment was developed. Two groups were defined based on smoking status: group 1 included smokers (more than 10 cigarettes/day) and former smokers, and group 2 included non-smokers. The data that resulted from the analysis of the cohort of patients demonstrate that smoking status does not affect the response of biologic therapy in patients with moderate and severe psoriasis.

show abstract

Impact of smoking on psoriasis risk and treatment efficacy: a meta-analysis

Cited by 44 publications

References 68 publications

Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life

Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life

Association of Nonalcoholic Hepatic Fibrosis with Body Composition in Female and Male Psoriasis Patients

The Impact of Smoking on Psoriasis Patients with Biological Therapies in a Bucharest Hospital

Contact Info

Product

Resources

About